Trials / Terminated
TerminatedNCT00695643
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 345 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether mesalazine granules compared to placebo is effective in prevention of recurrence of disease.
Detailed description
The purpose of the study is to demonstrate the superiority of mesalazine granules compared to placebo in terms of the primary efficacy variable proportion of recurrence-free patients within 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesalazine | 3 g per day |
| DRUG | Placebo | 0 g per day |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-11-01
- Completion
- 2012-01-01
- First posted
- 2008-06-12
- Last updated
- 2017-07-24
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00695643. Inclusion in this directory is not an endorsement.